Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Change in Cash (2020 - 2025)

Bioventus (BVS) has disclosed Change in Cash for 6 consecutive years, with $9.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Cash rose 708.18% year-over-year to $9.1 million, compared with a TTM value of $9.7 million through Dec 2025, up 109.09%, and an annual FY2025 reading of $9.7 million, up 109.09% over the prior year.
  • Change in Cash was $9.1 million for Q4 2025 at Bioventus, down from $9.3 million in the prior quarter.
  • Across five years, Change in Cash topped out at $42.6 million in Q2 2021 and bottomed at -$41.7 million in Q3 2022.
  • Average Change in Cash over 5 years is -$1.8 million, with a median of -$2.0 million recorded in 2022.
  • The sharpest move saw Change in Cash crashed 583.55% in 2022, then surged 708.18% in 2025.
  • Year by year, Change in Cash stood at -$31.7 million in 2021, then soared by 91.97% to -$2.5 million in 2022, then surged by 498.31% to $10.1 million in 2023, then tumbled by 114.72% to -$1.5 million in 2024, then soared by 708.18% to $9.1 million in 2025.
  • Business Quant data shows Change in Cash for BVS at $9.1 million in Q4 2025, $9.3 million in Q3 2025, and $10.1 million in Q2 2025.